1.
Clin J Oncol Nurs
; 20(5): 466-9, 2016 Oct 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27668365
RESUMO
Blinatumomab (Blincyto®) has received accelerated approval for treatment of relapsed or refractory acute lymphoblastic leukemia. This article describes the authors' experience with a multidisciplinary collaboration among nursing, pharmacy, prescribers, and support staff, which has proven to be key for safe administration. The approach can be applied to other institutions planning to use blinatumomab.